Welcome to LookChem.com Sign In|Join Free

CAS

  • or

153223-21-3

Post Buying Request

153223-21-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

153223-21-3 Usage

Description

(4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis(cyclopropylmethyl)-5,6-dihydroxy-1,3-diazepan-2-one is a complex organic compound characterized by a diazepane core structure. It features two benzyl groups and two cyclopropylmethyl groups attached to the diazepane ring, along with two hydroxyl groups at positions 5 and 6. This chemical is expected to exhibit significant biological activity, potentially influencing processes related to diazepane-like structures, such as neurotransmission or receptor modulation. However, further research is required to comprehensively understand its properties and potential applications.

Uses

Used in Pharmaceutical Industry:
(4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis(cyclopropylmethyl)-5,6-dihydroxy-1,3-diazepan-2-one is used as a potential pharmaceutical agent for [application reason] due to its significant biological activity and the possibility of impacting neurotransmission or receptor activity.
Used in Chemical Research:
In the field of chemical research, (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis(cyclopropylmethyl)-5,6-dihydroxy-1,3-diazepan-2-one serves as a subject of study to explore its properties, potential applications, and the mechanisms of action in biological systems.

Check Digit Verification of cas no

The CAS Registry Mumber 153223-21-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,2,2 and 3 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 153223-21:
(8*1)+(7*5)+(6*3)+(5*2)+(4*2)+(3*3)+(2*2)+(1*1)=93
93 % 10 = 3
So 153223-21-3 is a valid CAS Registry Number.

153223-21-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name (4R,5S,6S,7R)-4,7-dibenzyl-1,3-bis(cyclopropylmethyl)-5,6-dihydroxy-1,3-diazepan-2-one

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:153223-21-3 SDS

153223-21-3Relevant articles and documents

Calculated and experimental low-energy conformations of cyclic urea HIV protease inhibitors

Hodge, C. Nicholas,Lam, Patrick Y. S.,Eyermann, Charles J.,Jadhav, Prabhakar K.,Ru,Fernandez, Christina H.,De Lucca, George V.,Chang, Chong-Hwan,Kaltenbach III, Robert F.,Holler, Edward R.,Woerner, Francis,Daneker, Wayne F.,Emmett, George,Calabrese, Joseph C.,Aldrich, Paul E.

, p. 4570 - 4581 (2007/10/03)

One important factor influencing the affinity of a flexible ligand for a receptor is the internal strain energy required to attain the bound conformation. Calculation of fully equilibrated ensembles of bound and free ligand and receptor conformations are computationally not possible for most systems of biological interest; therefore, the qualitative evaluation of a novel structure as a potential high- affinity ligand for a given receptor can benefit from taking into account both the bound and unbound (usually aqueous) low-energy geometries of the ligand and the difference in their internal energies. Although many techniques for computationally generating and evaluating the conformational preferences of small molecules are available, there are a limited number of studies of complex organics that compare calculated and experimentally observed conformations. To assess our ability to predict a priori favored conformations of cyclic HIV protease (HIV-1 PR) inhibitors, conformational minima for nine 4,7- bis(phenylmethyl)-2H-1,3-diazepin-2-ones I (cyclic ureas) were calculated using a high temperature quenched dynamics (QD) protocol. Single crystal X-ray and aqueous NMR structures of free cyclic ureas were obtained, and the calculated low-energy conformations compared with the experimentally observed structures. In each case the ring conformation observed experimentally is also found in the lowest energy structure of the QD analysis, although significantly different ring conformations are observed at only slightly higher energy. The 4- and 7-benzyl groups retain similar orientations in calculated and experimental structures, but torsion angles of substituents on the urea nitrogens differ in several cases. The data on experimental and calculated cyclic urea conformations and their binding affinities to HIV-1 PR are proposed as a useful dataset for assessing affinity prediction methods.

Preparation and structure-activity relationship of novel P1/P1'- substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors

Nugiel,Jacobs,Worley,Patel,Kaltenbach III,Meyer,Jadhav,De Lucca,Smyser,Klabe,Bacheler,Rayner,Seitz

, p. 2156 - 2169 (2007/10/03)

A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 153223-21-3